FDA Approves New and Updated Indications for Temozolomide Under Project Renewal

FDA Approves New and Updated Indications for Temozolomide Under Project Renewal

On September 14, the US Food and Drug Administration (FDA) approved updated labeling for temozolomide under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date.

For more information read the FDA announcement.

Posted 9/21/2023

Upcoming Events

ACCC Oncology Reimbursement Meeting | Reno

ACCC Oncology Reimbursement Meeting | Reno

In Person November 4, 2026 at 8:00 AM PST255 North Virginia Street, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton,
ACCC Oncology Reimbursement Meeting | Providence

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,